Sevelamer
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Metabolic Bone Disease Medications | Sevelamer | Dose based on blood work | Administer with meals |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 150 | <0.02 | N/A | N/A | N/A | N/A | N/A | N/A |
References:
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00658
- Goldsmith D, Scott L, Cvetkovi R et al. Sevelamer Hydrochloride - A Review of its Use for Hyperphosphataemia in Patients with End-Stage Renal Disease on Haemodialysis. Drugs 2008; 68(1), 85-104.